Jonathan Yen-Wen Yu, serving as the Chief Operating Officer for Disc Medicine, Inc. (NASDAQ:IRON), has completed a transaction involving the disposition of 100 shares of the company's common stock. This sale took place on July 7, 2026, with the shares being sold at a price of $82.50 each, culminating in a total value of $8,250. The current trading price of the stock is recorded at $78.91, which represents a decline from the price at which Mr. Yu executed his sale. Despite this recent downward movement, the stock has delivered a 41% return over the past year. Market analysis indicates that Disc Medicine's stock exhibits high volatility, characterized by a beta of 2.07. Current assessments suggest that the company is overvalued relative to its Fair Value.
The sale was executed in conjunction with the exercise of stock options. Through this process, Mr. Yu acquired 100 shares of Disc Medicine common stock at a price of $13.50 per share, amounting to $1,350. Both the acquisition and the subsequent sale were carried out under a Rule 10b5-1 trading plan, which Mr. Yu adopted on March 17, 2026. Following these transactions, Mr. Yu directly holds 54,324 shares of Disc Medicine common stock. The stock options exercised were part of a grant where the underlying shares vest in 48 equal monthly installments following December 29, 2022, contingent on Mr. Yu’s continued service. After the exercise, Mr. Yu holds 23,747 derivative securities (stock options).
In other recent news, Disc Medicine Inc. presented updated clinical trial data for its investigational treatments at the European Hematology Association Annual Meeting. The RALLY-MF trial enrolled 61 adult patients with myelofibrosis and anemia, with 50 patients included in the responder analysis. Additionally, Disc Medicine completed a Type A meeting with the U.S. Food and Drug Administration regarding the Complete Response Letter for bitopertin in erythropoietic protoporphyria. The FDA agreed that the ongoing Phase 3 APOLLO study could potentially support a traditional approval if successful. Stifel reiterated a Buy rating and a $111.00 price target on Disc Medicine following the presentation of Phase 2 RALLY-MF trial data. Furthermore, Disc Medicine launched an expanded access program for bitopertin in the U.S. for patients with erythropoietic protoporphyria and X-linked protoporphyria. This program is intended for eligible patients who lack satisfactory therapeutic alternatives.